NCT03606967 2026-04-17
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07391670 2026-04-17
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT06117891 2026-04-15
REFINE-IO
Bayer
Recruiting
NCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07489976 2026-03-27
IIT2025-03-YANG-LIFT-HCC
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT04499053 2026-03-16
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Georgetown University
Phase 2 Recruiting
NCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06904170 2026-02-03
ALICE
UNICANCER
Phase 2/3 Recruiting
NCT07174570 2026-01-28
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
Phase 2 Recruiting
NCT03539822 2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2 Recruiting